NEWS
LATEST
FULL LIST
-
Organovo Sells FXR Drug Program to Eli Lilly in Strategic Deal to Advance IBD Therapies
Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical-stage biotechnology company pioneering 3D tissue-based drug discovery, announced today the successful completion of the sale of its FXR program—including lead therapeutic candidate FXR314—to Eli Lilly and Company (NYSE: LLY). The transaction, finalized on March 25, 2025, grants Lilly all commercial and intellectual property rights associated with Organovo’s FXR…
-
LyGenesis Receives Green Light to Advance Organ Regeneration Trial
LyGenesis, a clinical-stage biotech company pioneering a bold new approach to organ regeneration, has just hit an important milestone in its clinical trial for treating end-stage liver disease (ESLD). The company announced that an independent Data and Safety Monitoring Board (DSMB) has approved the continuation and dose escalation of its ongoing Phase 2a clinical trial.…
-
How Cellino and Matricelf are Advancing Neural Tissue Engineering
Introduction Cellino and Matricelf have announced a global collaboration aimed at advancing personalized treatments for spinal cord injuries. The partnership brings together innovative biomanufacturing and regenerative techniques to develop scalable, patient-specific therapies. Partnership Overview The collaboration leverages Cellino’s Nebula™ technology—an automated, closed-cassette system for producing high-quality induced pluripotent stem cells (iPSCs)—and Matricelf’s proprietary double autologous…
-
CollPlant Biotechnologies Update – Reports Q3 2024 Results, Advances Regenerative Breast Implant Program
Overview and Key HighlightsREHOVOT, Israel – CollPlant Biotechnologies, a developer of non–animal-derived collagen technologies for tissue regeneration and medical aesthetics, released its third quarter 2024 financial results and provided a corporate update on November 27, 2024. Preclinical Study SuccessA key highlight of the update was the promising outcome from a preclinical study evaluating CollPlant’s commercial-scale,…
-
Vericel – Poised for Growth with Expanding Indications and Strong Margins
Vericel (NASDAQ:VCEL) has established itself as a key player in regenerative medicine, yet the market continues to undervalue its potential. Unlike biotech firms chasing high-risk blockbuster drug approvals, Vericel has built a solid foundation with FDA-approved products—MACI, Epicel, and NexoBrid—delivering steady revenue growth and strong financials. With a notable 16% year-over-year revenue increase and zero…
-
Sernova Biotherapeutics Secures FDA Clearance for Thyroid Cell Pouch IND Application
Sernova Biotherapeutics has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application. The clearance enables the company to evaluate its Cell Pouch bio-hybrid organ, integrated with autologous thyroid cells, in patients undergoing thyroid surgery for nodular thyroid disease—a condition that often leads to hypothyroidism due to reduced thyroid hormone…
-
Nurami Medical Secures $30 Million to Accelerate Meningeal Tissue Repair Innovation
Nurami Medical, a Haifa‐based biomedical startup, has closed a $30 million funding round to advance its innovative approach to meningeal tissue repair. The company, led by co-founder Nora Nseir and her partner Dr. Amir Bahar, is focused on developing products that support the regeneration of meningeal tissue following complex brain and spinal cord surgeries. The…
-
Trestle Bio Announces Research Collaboration with Humacyte
Trestle Biotherapeutics, Inc. today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical-stage company working on bioengineered kidney tissues for patients with end stage renal disease (ESRD). The collaboration will investigate potential technological synergies…
-
Xenotransplantation Advances: United Therapuetics and eGensis Companies to Watch
In a significant development for the field of xenotransplantation, two biotech companies have recently received critical regulatory approvals that could reshape the future of organ transplantation. Following early clinical successes and notable setbacks, industry leaders are now advancing clinical trials aimed at addressing the chronic shortage of human organs for transplant. The concept of xenotransplantation…
-
ARMI BioFabUSA A Catalyst for Regenerative Medicine
Bringing Biofabrication Companies Together The Advanced Regenerative Manufacturing Institute (ARMI) is leading the charge in revolutionizing the bioeconomy of the United States. As a member-based nonprofit, ARMI operates through its flagship initiative, BioFabUSA, which fosters collaboration among more than 200 partners, including corporations, academic institutions, and nonprofits. The goal: to develop scalable, consistent, and cost-effective…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 